New data from insurers show detriments of copay accumulator adjustment programs
By Katie Koziara | April 28, 2021
Commercial health insurers are starting to admit what the biopharmaceutical research industry has been warning for some time: copay accumulator adjustment programs hurt patient outcomes and shift...
Read More
West Virginia becomes the first state to lower patient costs by sharing the savings
By Scott LaGanga | April 20, 2021
In a historic moment for patient affordability, last week West Virginia became the first state in the nation to adopt ground-breaking legislation, HB2263, requiring insurers and their PBMs to...
Read More
Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter
By Katie Koziara | March 2, 2021
A new study published in Health Affairs finds that for nearly 40% of commercially insured patients, half of their annual out-of-pocket expenses for medical treatments come from just one hospital,...
Read More
Top five issues voters want addressed in the administration’s first 100 days
By Mark Keida | February 18, 2021
When voters cast their ballots in the 2020 election, they made clear their focus on getting COVID-19 under control and fixing the economy. However, health care was still important to many voters,...
Read More
Insurers shift medicine costs to patients with severe chronic illnesses
By Gabby Migliara | February 1, 2021
For many patients with complex and chronic conditions, high out-of-pocket costs for medicines pose a significant challenge. Recent research revealed a broken insurance system that fails to help...
Read More
The latest misleading “poll” on drug pricing
By Brian Newell | January 28, 2021
When a front group for insurers and drug cost middlemen promote a poll on drug pricing, everyone’s immediate reaction should include a healthy dose of skepticism. The same is true for a poll from...
Read More
New insulin report highlights how incentives benefit middlemen, harm patients
By Brian Newell | January 22, 2021
The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...
Read More
Key facts: The final rebate rule will be a positive change for patients
By Tom Wilbur | January 19, 2021
While drug middlemen are making billions of dollars in record profits at a time when millions of Americans are facing financial struggles, they are also suing to block the final rebate rule, a...
Read More
Election insights: Voter priorities in the states
By Nick McGee | December 17, 2020
In the 2020 election, Americans nationwide cast their ballots with two major issues on their minds – the economy and coronavirus. Health care specific concerns centered on pre-existing conditions...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
